NIKKEI 225
26,402.84 -508.36 (-1.89%) HANG SENG
20,151.83 -492.45 (-2.39%) CRUDE OIL
110.31 +0.72 (+0.66%) GOLD FUTURES
1,810.90 -5.00 (-0.28%) DOW
31,490.07 -1,164.52 (-3.57%) BTC-GBP
23,633.07 -681.25 (-2.80%)
Orphazyme A/S (ORPHA.CO)
- Globe Newswire
Restructuring Proposal
Orphazyme A/S in restructuringCompany announcementNo. 26/2022 Inside informationwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 18, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors foll
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Globe Newswire
Updated Financial Calendar for 2022
Orphazyme A/S in restructuringCompany announcement No. 25/2022www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 16, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities durin
